Here are Antti’s pre-comments as Orion reports its Q1 results on Thursday, April 23rd. 
We expect strong revenue and earnings growth from Orion, supported particularly by Nubeqa. We forecast 2026 to be a period of steady growth for Orion, supported by highly predictable drivers. In contrast, important binary research results are expected in 2027–28, which will significantly impact future potential.
And here are Antti’s comments on the company’s recent news
Orion announced on Monday that its cancer drug candidate ODM-212 has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of mesothelioma. ODD status provides financial incentives and protects the drug’s commercial potential in the future. This positive news in itself has no impact on our view of the risk level or schedule of the ODM-212 development program.